1 completed, 1 recruiting. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Hormone Receptor Positive: new trials by email Literature Review of Hormone Receptor Positive trials Research Report on Hormone Receptor Positive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer Patritumab deruxtecan, Trastuzumab deruxtecan - Hormone Receptor Positive, HER2-low or HER2-ultralow | Phase 1 / Phase 2 | Recruiting | Daiichi Sankyo | 220 | 2026-09-17 | 2026-10-01 |
| First in Human Evaluation of Safety, Pharmacokinetics, and Clinical Activity of a Monoclonal Antibody Targeting Netrin 1 in Patients With Advanced/Metastatic Solid Tumors NP137 DL and RP2D - Advanced Solid Tumor, Endometrial Carcinoma | Phase 1 | Completed | Centre Leon Berard | 70 | 2017-01-09 | 2022-07-25 |
Breast Neoplasms (1) · Endometrial Neoplasms (1)
Neoplasms (2) · Neoplasms by Site (2) · Breast Diseases (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Genital Diseases (1) · Genital Diseases, Female (1) · Genital Neoplasms, Female (1) · Skin Diseases (1) · Skin and Connective Tissue Diseases (1) · Urogenital Diseases (1) · Urogenital Neoplasms (1) · Uterine Diseases (1) · Uterine Neoplasms (1)
patritumab deruxtecan (1) · trastuzumab deruxtecan (1)
Centre Leon Berard (1) · Daiichi Sankyo (1)
France (2) · Belgium (1) · Italy (1) · Japan (1) · South Korea (1) · Spain (1) · Taiwan (1) · United States (1)
2015 (1)